NASDAQ
15.85USD
-0.28 (-1.74%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2B
P/E
—
EPS
—
Beta
1.42
52W range
10.34-19.25
Day range
15.60–16.59
Open
16.24
Prev close
16.13
Volume
1.5M
Avg volume
1.5M
Dividend
0.00
IPO
2014-09-03
https://www.zacks.com/stock/news/2957811/karyopharm-therapeutics-kpti-soars-5-3-is-further-upside-left-in-the-stock?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|daily_price_change_5%-2957811 · 7/22/2026+0.20
https://www.fool.com/coverage/filings/2026/06/07/ceo-buys-auph-815k-shares-for-125-million/ · 6/7/2026+1.00
https://www.zacks.com/stock/news/2906254/ars-pharmaceuticals-inc-spry-soars-7-1-is-further-upside-left-in-the-stock?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|daily_price_change_5%-2906254 · 4/23/2026+0.40
https://www.benzinga.com/trading-ideas/movers/26/02/50909292/aurinia-pharmaceuticals-auph-stock-drops-after-strong-quarter-softer-forward-revenue-targets · 2/26/2026-0.40
https://www.investors.com/stock-lists/stock-spotlight/pharma-stock-aurinia-pharmaceuticals-auph-earnings-growth-bullish-base/ · 2/6/2026+0.60
https://www.zacks.com/stock/news/2794804/is-aurinia-pharmaceuticals-auph-stock-outpacing-its-medical-peers-this-year?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_1-2794804 · 11/24/2025+1.00
https://seekingalpha.com/article/4832182-aurinia-pharmaceuticals-lupkynis-growth-and-aur200-pipeline-justify-buy-rating · 10/23/2025+1.00
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
